Tesamorelin

Dosing and treatment duration

Why 2 mg appears so often

A 2 mg injection under the skin once daily belongs to an older tesamorelin formulation. Other formulations use different amounts and mixing instructions. Confirm the exact preparation before using that number; it is not a dose for every vial labelled tesamorelin.

Current prescription formulations

The labelled daily doses are 1.4 mg for EGRIFTA SV and 1.28 mg for EGRIFTA WR, both subcutaneous. These formulations are not substitutable. Their different numbers are not interchangeable options to choose according to a fat-loss goal.

For any prescribed preparation, keep the formulation, amount, concentration and volume together. A mass such as 1.4 mg is different from the liquid volume used to deliver it.

How long before judging a result?

Assess progress over months, not days. Scale weight alone cannot tell you whether deep abdominal fat is changing. Agree on the measurements and review dates before starting.

Deep abdominal fat can return after treatment stops. Tesamorelin should not be approached as a short course that permanently removes this fat.

A treatment review should consider benefit, symptoms and monitoring results together. A plateau alone is not a reason to increase an amount or extend treatment indefinitely.

Timing and missed doses

The current prescription schedules are once daily. Their labels do not require a universal bedtime or fasting schedule. Online rules about mandatory fasting should not be presented as established requirements for all tesamorelin preparations.

For a missed dose, follow the prescribed instructions; do not double the next dose to compensate.

Oral versus SubQ

Why swallowing it is different

The digestive system is designed to break down proteins and peptides. Enzymes can cut them into smaller fragments, while the intestinal lining limits how much intact peptide reaches the blood.

Tesamorelin needs to reach the circulation to act on the pituitary. Simply swallowing the same number of milligrams does not reproduce an injected amount.

Could oral tesamorelin work directly on the gut?

Tesamorelin needs to reach the hormone-signalling system. Its purpose is not to act on the surface of the gut. Poor oral absorption therefore does not provide a useful local-gut advantage for this peptide.

Do not convert an injection dose into an oral or nasal amount. Changing the route changes absorption, and the same milligram amount may not produce the same effect.

What SubQ means

Subcutaneous, or SubQ, means delivery into fatty tissue beneath the skin. This bypasses digestive processing, although absorption still occurs from the injection site. It should not be described as automatically delivering 100% of the amount to the bloodstream.

Preparation and reconstitution

Reconstitution means adding the specified water to a lyophilised (freeze-dried) peptide to prepare a solution. Bacteriostatic water contains a preservative and is used for some formulations, including tesamorelin WR. Tesamorelin SV requires its supplied sterile water instead. The type of water and the volume must match the formulation’s preparation instructions.

Before opening the supplies

Check the peptide name, vial strength, expiry and preparation instructions. Confirm that the diluent belongs with that formulation. Have a clean preparation area, the instructed sterile supplies and a sharps container ready.

Tesamorelin formulations have different mixing instructions. The two examples below apply only to the named preparations. Their diluents and volumes must not be copied onto a different vial.

SV formulation

For EGRIFTA SV, add 0.5 mL of the supplied sterile water to its 2 mg vial. Roll gently for 30 seconds; do not shake. The concentration is 4 mg/mL. Its labelled 1.4 mg dose occupies 0.35 mL. Use immediately and discard the remainder.

WR formulation

For EGRIFTA WR, add 1.3 mL of its supplied bacteriostatic water to the 11.6 mg vial. Swirl; do not shake. The labelled concentration is 8 mg/mL and the 1.28 mg dose occupies 0.16 mL. Do not recalculate concentration by simply dividing the printed vial mass by the added liquid.

What the different waters mean

Sterile water has no antimicrobial preservative. Bacteriostatic water contains a preservative. They are not automatically interchangeable, and a preservative does not sterilize contaminated powder.

A research-use-only vial does not become a documented injectable medicine when water is added. Its label alone cannot establish a suitable human preparation method.

Inspect and record

Follow the preparation’s inspection instructions. Do not use a solution that is cloudy, discolored or contains particles when it is supposed to be clear. Record the mixing date, final concentration and instructed discard date. Appearance alone cannot establish sterility.

Administration

Tesamorelin’s prescription instructions specify injection under the skin into the abdomen, rotating sites and avoiding the navel, bruises and scar tissue. The needle goes into tissue beneath the skin—not deep into the abdomen or into visceral fat.

Use the supplied or prescribed injection equipment and the technique demonstrated by the treating team. Do not choose a longer needle to “reach belly fat.” Needle length, angle and technique should suit the person and equipment.

Use a new needle and syringe each time, never share supplies, and place used sharps in the appropriate container. Avoid inflamed or infected skin. Repeated local reactions deserve review of the preparation and technique.

Syringe markings are volume

On a U-100 insulin syringe, 100 marked units equal 1 mL. Those markings are not milligrams of tesamorelin or units of growth-hormone activity. A saved instruction such as “use 20 units” becomes ambiguous if the concentration changes. Record the mass and concentration as well as volume.

Half-life

Approximately 8 minutes for SV and 11 minutes for WR, measured after their respective single subcutaneous doses in healthy subjects.

This is how quickly tesamorelin is cleared from blood—not how long the hormonal response or body-composition changes last. It does not imply that doses should be repeated every few minutes.

Storage

Storage belongs to the formulation, not just the peptide name.

SV powder is stored at 20–25°C with light protection. After mixing, use it immediately; do not refrigerate or freeze the mixed solution for later use.

WR mixed solution is stored at 20–25°C and discarded seven days after mixing; do not freeze it. A vial providing a week’s supply does not mean the medicine is injected once weekly.

For a different preparation, obtain its own documented storage and discard instructions. Do not transfer either example to it. Refrigerating every mixed peptide is not a universal rule.

When travelling, record any significant temperature excursion and seek advice on the affected preparation. Re-cooling a vial does not reset its expiry or prove it remained stable.

Contraindications and precautions

When tesamorelin should not be used

Clinical contraindications include active cancer, pregnancy, serious allergy to tesamorelin or its ingredients, and disruption of the hypothalamic-pituitary system, such as certain pituitary disease, surgery, irradiation or injury.

Conditions needing additional review

A history of treated cancer, diabetes or elevated glucose, and breastfeeding require individual assessment. Safety and effectiveness in children have not been established.

Tell the treating clinician about other hormone-active treatments and steroid replacement for adrenal insufficiency. A combination can change monitoring or medication requirements; it is not simply a stronger version of tesamorelin alone.

“Not an absolute contraindication” does not mean “nothing to check.” The practical question is whether the expected benefit justifies the risks for that person.

Side effects and monitoring

Possible effects include joint or muscle discomfort, swelling, tingling or carpal-tunnel-type symptoms, and injection-site reactions. Changes in glucose or IGF-1 may occur without an obvious symptom.

Agree a monitoring plan with the treating clinician, including glucose assessment and IGF-1. Do not interpret rising IGF-1 as a score to maximize. New swelling also should not automatically be logged as muscle gain.

Seek emergency care for trouble breathing, facial or throat swelling, or fainting after an injection. Report persistent or worsening local reactions promptly.

Tracking progress in Peptscape

A useful record connects what was used, what changed and when.

• Preparation: exact formulation, vial strength, concentration and mixing date.

• Administration: amount, volume, route, time and injection site.

• Measurements: weight and waist recorded consistently, with the same measurement method.

• Observations: swelling, discomfort, sleep, appetite and changes in training or food intake.

• Clinical follow-up: dated glucose and IGF-1 results, with clinician interpretation.

These are suggested record fields for reviewing this content, not a claim that every field is already implemented in the app.

A home scale’s visceral-fat estimate is not a direct measurement of deep abdominal fat. Record the trend, and review it alongside your clinical assessment rather than changing a dose after one reading.